Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

Core Insights - Y-mAbs Therapeutics, Inc. presented preclinical and translational pharmacokinetics data of GD2-SADA at the SNMMI Mid-Winter and ACNM Annual Meeting, highlighting its focus on cancer treatment through novel radioimmunotherapy and antibody-based products [1][2] Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative cancer therapies, including the SADA Pretargeted Radioimmunotherapy Platform and bispecific antibodies [4] - The company’s product pipeline includes DANYELZA®, the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma [4] GD2-SADA PRIT Details - GD2-SADA is a bispecific fusion protein designed for pretargeted radioimmunotherapy, binding to GD2-expressing tumors and delivering a radioactive payload for localized treatment [5] - Preclinical studies have shown robust anti-tumor efficacy of GD2-SADA with Lutetium 177 [5] Research and Development - The pharmacokinetics study characterizes GD2-SADA plasma levels in animal models and informs the design of the ongoing first-in-human Phase 1 Trial (Trial 1001) [2][3] - The research was conducted by Memorial Sloan Kettering Cancer Center, which has licensed the SADA technology to Y-mAbs [3]